Medtronic and DaVita plan to form a joint venture to manufacture medical devices for kidney care. Medtronic will contribute the Renal Care Solutions business and related product portfolio, as well as global manufacturing R&D teams and facilities. The partners will have equal stakes in the venture. The joint venture is expected to be completed next year.

DaVita's GAAP net income for the 3 months of 2022 was $205.718 million, down 29.4% from $291.545 million in the previous year. Revenue declined 0.1% to $2.818 billion from $2.82 billion a year earlier.

DaVita's GAAP net income for 2021 was $1.212 billion, up 21.8% from $0.995 billion in the previous year. Revenue increased 0.6% to $11.619 billion from $11.551 billion a year earlier.

DaVita reported a GAAP net profit of $962.33 million for 9M 2021, up 26.6% from $760.307 million in the previous year. Revenue increased by 0.3% to $8.675 billion from $8.645 billion a year earlier.